Vesicor Therapeutics and Black Hawk Acquisition Corporation Announce Closing of Business Combination

On November 20, 2026 Vesicor Therapeutics Holdings, Inc. ("Vesicor" or the "Company"), an early development stage biotechnology company focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles, reported the closing of its previously announced business combination with Black Hawk Acquisition Corporation (Nasdaq: BKHA) ("Black Hawk"). The transaction was approved by Black Hawk’s shareholders at an extraordinary general meeting held on October 13, 2026 and closed on November 19, 2026. In connection with the closing, Black Hawk domesticated from the Cayman Islands to Delaware and changed its name to Vesicor Therapeutics Holdings, Inc. The Company’s common stock is expected to begin trading on the Nasdaq Capital Market under the ticker symbol "VESI" on November 23, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vesicor will be led by Michael Tolentino, MD, Chief Executive Officer; Luo Feng, PhD, Founder, Director and Chief Scientific Officer; Mitch Creem, MHA, Chief Financial Officer; and Warren Hosseinion, Jr., Chief Operating Officer. The Company’s Board of Directors consists of Warren Hosseinion, Sr., MD (Chairman), Luo Feng, PhD, Oded Levy, Frederick Woodruff Field and Qi Ouyang.

"Closing this transaction gives Vesicor access to the public markets at the point where the Company needs it most, as we prepare to begin IND-enabling studies for ecm-RV/p53," said Warren Hosseinion, Sr., MD, Chairman of the Board. "I want to thank our shareholders and the Vesicor team for the work that brought us here. Our focus now is execution."

"I founded Vesicor in 2008 with the goal of developing p53-based cancer therapeutics using precision-engineered microvesicles," said Luo Feng, PhD, Founder, Director and Chief Scientific Officer. "ecm-RV/p53 reflects many years of research, and we are focused on building on that foundation as we seek to advance the program toward clinical evaluation."

"Our priority as a public company is clear: advance ecm-RV/p53 through IND-enabling studies and toward an IND submission to the FDA," said Michael Tolentino, MD, Chief Executive Officer. "We have a defined goal, an experienced team and a board that has the skills to advance the priorities of the Company. We look forward to reporting our progress to shareholders."

Advisors

Celine & Partners, P.L.L.C. and Ogier Global (Cayman) Limited served as legal counsel to Black Hawk. D. Boral Capital LLC served as the capital markets advisor to Black Hawk. PW Richter PLC, Winston Taylor LLP, and Shartsis Friese LLP served as legal counsel to Vesicor.

(Press release, Vesicor Therapeutics, NOV 20, 2026, View Source [SID1234675051])

Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma

On November 20, 2026 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported the pivotal Phase 3 TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech, met its primary endpoint of overall survival (OS) compared to treatment of physician’s choice (TPC, consisting of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel) in the treatment of patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy. TroFuse-015 represents the first time a TROP2-directed ADC has demonstrated an OS benefit in a global Phase 3 trial in this patient population, where there is significant unmet need. These data will be presented at an upcoming medical meeting and shared with regulatory authorities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At final analysis, sac-TMT demonstrated a statistically significant and clinically meaningful improvement in OS compared to TPC for these patients who have received two or more prior lines of systemic therapy. Results were generally consistent across subgroups regardless of TROP2 expression status. Sac-TMT did not meet the secondary endpoint of progression-free survival (PFS) assessed by blinded independent central review (BICR). Additionally, sac-TMT showed a nominally improved benefit in objective response rate (ORR), a secondary endpoint, favoring sac-TMT compared with TPC, but this was not formally tested under the prespecified analysis plan. The safety profile was consistent with what has been observed in previously reported studies of sac-TMT; no new safety signals were observed.

"Sac-TMT is the first TROP2 ADC to improve OS in a global Phase 3 study in advanced gastroesophageal adenocarcinoma compared to TPC, demonstrating its potential in a particularly challenging disease setting," said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. "There is a tremendous unmet need for therapies that can improve survival for these patients. We look forward to discussing these data with regulatory authorities and sharing with the scientific community on behalf of patients who may benefit."​

TroFuse-015 also marks the second positive Phase 3 study from Merck’s TroFuse clinical development program for sac-TMT. The program currently consists of 18 ongoing global Phase 3 trials across multiple tumor types, the broadest range of disease and treatment settings compared to any TROP2-directed ADC to date. The program is evaluating sac-TMT across a diverse range of tumor types, including endometrial, bladder, breast, cervical, gastric, non-small cell lung and ovarian cancers, and it spans early-to-late-stage disease as both monotherapy and in combination with immunotherapies. Within the program, 14 of the 18 Phase 3 studies are pursuing first-in-class opportunities to address unmet medical needs, including TroFuse-015.

About TroFuse-015
TroFuse-015 is a randomized, open-label, multicenter, global Phase 3 trial (ClinicalTrials.gov, NCT06356311) evaluating the efficacy and safety of the TROP2-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) compared to the treatment of physician’s choice (TPC) in participants with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy. The trial enrolled 473 patients who were randomized to receive either sac-TMT or TPC, consisting of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Sac-TMT (4 mg/kg) was administered on Days 1, 15 and 29 of each six-week treatment cycle. Trifluridine-tipiracil (35 mg/m²) was administered orally twice daily on Days 1-5 and 8-12 of each four-week treatment cycle. Irinotecan (150 mg/m²) was administered on Days 1 and 15 of each four-week treatment cycle. Paclitaxel (80 mg/m²) was administered on Days 1, 8 and 15 of each four-week treatment cycle. Docetaxel (75 mg/m²) was administered on Day 1 of each three-week treatment cycle.

The study has a primary endpoint of overall survival. Secondary endpoints include progression-free survival, objective response rate, and duration of response.

About sacituzumab tirumotecan (sac-TMT)
Sac-TMT is an investigational TROP2-directed ADC with a belotecan-derived topoisomerase I inhibitor payload and a unique bifunctional linker designed with the potential to maximize payload delivery to tumor cells and minimize payload loss while circulating in the body.

TROP2 is overexpressed on tumor cells compared to healthy cells in many common cancers, and through the TroFuse clinical development program, Merck is evaluating sac-TMT in 18 ongoing global Phase 3 trials across multiple tumor types, the broadest range of disease and treatment settings compared to any TROP2-directed ADC to date. The TroFuse development program spans early-to-late stage disease in more than nine disease areas and includes more than 15,000 patients worldwide. Numerous Phase 3 trials are exploring sac-TMT as monotherapy and in combination with immunotherapies, aiming to improve survival and quality of life for patients with advanced and earlier-stage cancers.

About Gastroesophageal Adenocarcinoma
Gastroesophageal adenocarcinoma comprises gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinomas (EAC).

Gastric (stomach) cancer often does not cause symptoms in its early stages, making it difficult to detect before the disease has advanced. Most gastric cancers are adenocarcinomas, accounting for approximately 90% to 95% of gastric malignancies, which develop from cells in the innermost lining of the stomach, known as the mucosa. In the U.S., it is estimated there will be approximately 31,500 new cases of gastric cancer and 10,700 deaths from the disease in 2026. Gastric cancer accounts for approximately 1.5% of all new cancers diagnosed in the U.S. each year.

Esophageal cancer starts when cells in the lining of the esophagus begin to grow out of control. In the U.S., about 68% of all new cases of esophageal cancer are EAC, and it is estimated there will be more than 14,300 new cases of EAC in 2026. Approximately 42% of EAC patients in the U.S. are diagnosed at the distant disease stage.

(Press release, Merck & Co, NOV 20, 2026, View Source [SID1234675036])

Merck and Isomorphic Labs Enter Strategic Research Collaboration

On November 19, 2026 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, reported a research collaboration that brings together Isomorphic Labs’ AI approach to drug discovery with Merck’s rich proprietary data resources and deep discovery experience.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The companies will collaborate to discover therapeutic small molecule candidates against an oncology target of strategic importance. Isomorphic Labs will perform in silico predictions and deliver molecular designs, applying its proprietary drug design engine (IsoDDE) incorporating select high-quality proprietary data sets supplied by Merck for the purpose of this collaboration. Merck will be responsible for preclinical and clinical development, as well as manufacturing and commercialization of any products derived from the collaboration.

Under the terms of the agreement, Isomorphic Labs will receive an upfront payment from Merck and be eligible for payments based on the achievement of specified research, development, regulatory and commercial milestones, as well as tiered royalties on net sales. Isomorphic Labs also receives an option to co-fund development activities in return for elevated royalties.

"The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions," said George Addona, senior vice president and head of discovery, preclinical development and translational medicine, Merck Research Laboratories. "By combining Merck’s substantial internal data capabilities and discovery expertise with Isomorphic Labs’ powerful modeling and compute capabilities, we aim to identify new ways to design and create better candidates faster."

"Through this collaboration with Merck, we will apply our world-leading drug design engine to unlock significant discovery progress," said Sarah Skerratt, chief research officer, Isomorphic Labs. "By leveraging the generative and predictive power of the IsoDDE to address this challenging program, this collaboration highlights our companies’ shared commitment to innovation for the benefit of patient populations with unmet needs."

The collaboration highlights the transformative power of bringing together advanced AI, unique data sets and established biopharmaceutical leadership to accelerate the advancement of therapeutic candidates, navigating complex biology with unprecedented speed and precision.

(Press release, Merck & Co, NOV 19, 2026, View Source [SID1234674997])

Remix Therapeutics Announces Updated Positive REM-422 Phase 1 Data in Adenoid Cystic Carcinoma at 2026 EORTC-NCI-AACR Symposium

On November 19, 2026 Remix Therapeutics, Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, reported updated Phase 1 data from its ongoing ARIA Phase 1/2 study of REM-422, an oral MYB mRNA degrader, in a late-breaking oral presentation at the 2026 EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium on Molecular Targets and Cancer Therapeutics. Durable responses, prolonged progression-free survival and continued favorable tolerability were observed in patients with biomarker-positive recurrent or metastatic adenoid cystic carcinoma (ACC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There are currently no FDA-approved therapies for patients with ACC, despite the urgent need for an effective treatment," said Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics. "The updated REM-422 data continue to reinforce the promise of our RNA-processing platform and highlight the potential of targeted MYB degradation to address the underlying biology of this disease. We are particularly encouraged by the 57% overall response rate observed at the recommended Phase 2 dose in biomarker-positive patients, the durability of responses extending beyond one year, and median progression-free survival that has not yet been reached. Together, these compelling findings support our confidence that REM-422 has the potential to become a meaningful long-term treatment option for ACC patients."

"The relationship between MYB biomarker status and clinical outcomes observed in this study is compelling," said Alan Ho, M.D., Ph.D., Chief of the Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center. "The ability to identify patients most likely to benefit, combined with the durability of activity seen to date, highlights the potential of this precision medicine approach in ACC and supports further evaluation of REM-422."

The ongoing Phase 1/2 ARIA study is evaluating REM-422 in patients with recurrent, metastatic or unresectable ACC. REM-422 is a first-in-class oral small molecule designed to bind a poison exon within MYB mRNA, inducing degradation of the transcript and reducing MYB protein expression. MYB dysregulation is a defining feature of ACC and represents a promising therapeutic target.
As of August 24, 2026, 69 patients had been enrolled in the Phase 1 study, including 60 efficacy-evaluable patients. REM-422 was generally well tolerated across all dose levels evaluated, with no dose-limiting toxicities observed. The potentially registrational Phase 2 study enrolling biomarker positive patients treated at dose of 24 mg is expected to complete enrollment by year end.

Key findings from the Phase 1 analysis, as of August 24, 2026 include:

Across all dose levels tested, 10 patients achieved a partial response (PR) among 32 efficacy-evaluable biomarker-positive (BM+) patients while no objective responses were observed among biomarker-negative patients.
At the recommended Phase 2 dose (RP2D) of 24 mg, the overall response rate was 57% (4 of 7 efficacy-evaluable BM+ patients) with three confirmed partial responses (1 of 3 was confirmed subsequent to data-cut) and one unconfirmed partial response.
Among BM+ patients median duration of response had not been reached, with responses ongoing up to 19 months.
Time on treatment in BM+ patients reached up to 27 months and remains ongoing.
Median progression-free survival was not reached in biomarker-positive patients, compared with 9 months in biomarker-negative patients at dose levels ≥ 24 mg.
MYB biomarker status emerged as the key predictor of both clinical and pharmacodynamic response, with responses observed across patient subgroups regardless of mutation status, prior therapies, histologic subtype, or primary tumor location.
The full ENA presentation can be accessed in the Presentations section of the Remix website.

About REM-422
REM-422 is a potent, selective, and oral small molecule mRNA degrader that induces the reduction of MYB mRNA and subsequent protein expression. REM-422 functions by facilitating the incorporation of a poison exon in the MYB mRNA transcript, leading to nonsense-mediated decay of the transcript. REM-422 is currently in Phase 1/2 clinical studies in both Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS). The U.S. Food and Drug Administration granted REM-422 Orphan Drug Designation for ACC and AML and Fast Track designation for ACC.

About the ARIA (A study of REM-422 In Adenoid cystic carcinoma) Clinical Trial
This Phase 1/2, open-label, non-randomized, multicenter study (NCT06118086) is investigating REM-422 in patients with recurrent, metastatic or unresectable Adenoid Cystic Carcinoma (ACC). The study includes a Dose Escalation Phase and a Dose Expansion Phase. The purpose of the Dose Escalation Phase is to determine the maximum tolerated dose and/or recommended Phase 2 dose (RP2D) of REM-422 in patients with recurrent, metastatic, or unresectable ACC. The purpose of dose expansion is to further evaluate the safety and anti-tumor activity of the REM-422 RP2D in biomarker positive patients.

About Adenoid Cystic Carcinoma
Adenoid cystic carcinoma (ACC) is solid tumor that that most commonly arises in the salivary glands, though it can also occur in the breast, trachea, skin, and other exocrine tissues, with the majority of cases involving the head and neck. The disease is characterized by frequent perineural invasion and, in the majority of cases dysregulation of the MYB oncogene. Depending on tumor location, symptoms may include facial numbness, difficulty swallowing, vision changes, or difficulty breathing. No systemic therapy is currently FDA-approved for recurrent or metastatic ACC. Surgery, often combined with radiation, remains the standard of care for localized disease, while chemotherapy, kinase inhibitors, and immunotherapy have all been studied in advanced disease with modest or disappointing results overall.

(Press release, Remix Therapeutics, NOV 19, 2026, View Source [SID1234675020])

Registrational Phase III AMPLIFY trial: Follow-up assessments completed for all participants

On November 19, 2026 Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, reported that the last patient has completed their final follow-up assessments in the Phase III diagnostic 64Cu-SAR-bisPSMA trial, AMPLIFY (NCT06970847)1.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AMPLIFY (64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants with Biochemical Recurrence of Prostate Cancer) is a non-randomised, single-arm, open-label, multi-centre, diagnostic clinical trial of 64Cu-SAR-bisPSMA positron emission tomography (PET) in participants with rising or detectable prostate-specific antigen (PSA) after initial definitive treatment at clinical sites across the US and Australia.

The aim of this registrational study is to investigate the diagnostic ability of 64Cu-SAR-bisPSMA PET/computed tomography (CT) to detect recurrence of prostate cancer in men with PSA levels above 0.2 ng/mL. The study co-primary endpoints are participant-level correct detection rate (CDR) and region-level positive predictive value (PPV) assessed independently for same-day and next-day imaging (1-4 hours and approximately 24 hours post-administration, respectively). The AMPLIFY study also has a number of exploratory endpoints, such as direct comparisons of 64Cu-SAR-bisPSMA to standard-of-care (SOC) prostate-specific membrane antigen (PSMA) PET agents.

AMPLIFY commenced in May 2025, seeking to enrol approximately 220 participants, and the first trial participant was imaged in the same month at XCancer with Dr Luke Nordquist (Omaha, NE). The target number of participants in the AMPLIFY study was achieved in March 2026, with the rapid pace of recruitment underscoring the substantial unmet need for improved diagnostic imaging in the biochemical recurrence (BCR) setting.

Most recently, Clarity was granted Breakthrough Therapy designation for 64Cu-SAR-bisPSMA in BCR of prostate cancer by the United States (US) Food and Drug Administration (FDA)2. Breakthrough Therapy designation is a process designed to expedite the development and review of products that are intended to treat a serious condition, and preliminary clinical evidence indicates that the agent may demonstrate substantial improvement over available products on a clinically significant endpoint(s)3. The Breakthrough Therapy designation was supported by the Phase I/IIa COBRA4 and Phase II Co-PSMA5 trials as well as real-world evidence6. This evidence has collectively demonstrated enhanced imaging capabilities of 64Cu-SAR-bisPSMA over SOC PSMA PET in patients with BCR of prostate cancer4-6.

The Breakthrough Therapy designation represents the latest in a series of US FDA recognitions for the SAR-bisPSMA platform. Prior to receiving Breakthrough Therapy designation, 64Cu-SAR-bisPSMA had already received two Fast Track designations spanning PET imaging in patients with suspected metastasis who are candidates for initial definitive therapy7 and those with BCR following definitive therapy8, with the latter supported primarily by data from the COBRA study4. This regulatory recognition extends across the broader SAR-bisPSMA program, with 67Cu-SAR-bisPSMA also receiving Fast Track designation for the treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) following androgen receptor pathway inhibitor [ARPI] and androgen deprivation therapy [ADT])9.

64Cu-SAR-bisPSMA is also currently being evaluated in another registrational Phase III trial, CLARIFY (NCT06056830)10, which is expected to complete last participant assessments in calendar year (CY) 2026. Building on the Phase I PROPELLER11 study, the objective of CLARIFY is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET across same-day and next-day imaging in detecting prostate cancer within the pelvic lymph nodes in patients who are scheduled to undergo radical prostatectomy and pelvic lymph node dissection.

Topline data from the AMPLIFY and CLARIFY trials are anticipated to be released in the first half of CY2027. As pivotal trials, the final study results are intended to provide sufficient evidence to support applications to the US FDA for approval of 64Cu-SAR-bisPSMA as a new diagnostic imaging agent in BCR (AMPLIFY) and in prostate cancer patients prior to undergoing definitive therapy (CLARIFY).

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, commented, "The completion of all patients’ follow-ups is an important step as our team and collaborators continue to work with all participating sites on the entry of the final data. This will be followed by analysis and release of topline results, expected in the first half of CY2027. We look forward to commencing our module submissions for our New Drug Application (NDA) with the US FDA under their rolling review process as part of the Breakthrough Therapy designation.

"What we find extraordinary about our SAR-bisPSMA BCR program is that, to our knowledge, this is the first time in the history of the US FDA Breakthrough Therapy designation program that an Australian company (Clarity) has received the designation for a product that was invented and developed, from the lab to the clinic, in Australia. Clarity is also the first company globally to receive Breakthrough Therapy designation for a PSMA PET imaging agent. Furthermore, of the more than 1,300 applications the US FDA has received for Breakthrough Therapy designation across all therapeutic areas, fewer than half have been awarded12, and we believe that only a single-digit number of diagnostics have received this designation. This is an incredible accomplishment, and we are proud to see this phenomenal Australian science story unfold.

"The Breakthrough Therapy and Fast Track designations awarded to 64Cu-SAR-bisPSMA further underscore the unmet need and help expedite the development of our optimised product in BCR of prostate cancer, with the goal of bringing it to patients who need it most, as fast as possible. With a next-generation product, we believe we are well positioned to address this growing market opportunity, predicted to exceed US$3Bn by 2029, while better serving patients and their clinicians in the pursuit of our ultimate goal to improve treatment outcomes for people with cancer."

About SAR-bisPSMA
SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

About Prostate Cancer
Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide13. Prostate cancer is the second-leading cause of cancer death in American men. The American Cancer Society estimates there will be about 333,830 new cases of prostate cancer in the US in 2026 and around 36,320 deaths from the disease.

(Press release, Clarity Pharmaceuticals, NOV 19, 2026, View Source [SID1234674909])